-
Mashup Score: 6Conference Update - 5 month(s) ago
MRD-Guided Ibrutinib plus Venetoclax Improves PFS in Untreated CLL Amy Herman In patients with untreated chronic lymphocytic leukemia (CLL), treatment with ibrutinib plus venetoclax, tailored according to measurable residual disease (MRD), is superior to fludarabine–cyclophosphamide–rituximab (FCR)…
Source: m.n.nejm.orgCategories: General Medicine News, General Journals & SocietTweet
-
Mashup Score: 5Conference Update - 5 month(s) ago
Adding Daratumumab in Newly Diagnosed Multiple Myeloma Improves PFS Amy Herman In transplant-eligible patients with newly diagnosed multiple myeloma, the addition of subcutaneous daratumumab to standard-of-care induction, consolidation, and maintenance therapy improves progression-free survival…
Source: m.n.nejm.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1Conference Update - 5 month(s) ago
First-Line T-DM1 Doesn’t Improve Survival in Older Patients with HER2+ Advanced Breast Cancer Cara Adler In older patients with human epidermal growth factor receptor 2 (HER2)–positive, metastatic breast cancer, first-line treatment with trastuzumab emtansine (T-DM1) did not improve overall survival but had better overall…
Source: m.n.nejm.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 2Conference Update - 5 month(s) ago
Nivolumab-AVD May Be Superior to Brentuximab Vedotin-AVD in Older Patients with Hodgkin’s Lymphoma Cara Adler For older patients with advanced Hodgkin’s lymphoma, nivolumab plus AVD chemotherapy (doxorubicin, vinblastine, dacarbazine) is associated with better survival outcomes and is better…
Source: m.n.nejm.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 2Conference Update - 5 month(s) ago
Patients with Metastatic Breast Cancer Benefit from Structured Exercise Amy Herman Patients with metastatic breast cancer who participated in a structured exercise program over 9 months experienced improvements in health-related quality of life and fatigue, according to the multinational, randomized, controlled PREFERABLE-EFFECT…
Source: m.n.nejm.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 9Conference Update - 5 month(s) ago
Some Patients May Safely Forego Regional Lymph Node Irradiation After Neoadjuvant Chemotherapy Cara Adler In patients with breast cancer whose axillary lymph nodes convert from positive at diagnosis to negative after neoadjuvant chemotherapy, regional nodal irradiation (RNI) does not appear to add a survival or recurrence benefit…
Source: m.n.nejm.orgCategories: General Medicine News, General Journals & SocietTweet
-
Mashup Score: 10Conference Update - 6 month(s) ago
Sparsentan Demonstrates Long-Term Efficacy, Safety in IgA Nephropathy Kelly Young Sparsentan, a dual endothelin–angiotensin receptor antagonist, slowed decline in kidney function in patients with immunoglobulin A (IgA) nephropathy, compared with irbesartan, according to results of the PROTECT study…
Source: m.n.nejm.orgCategories: General Medicine News, General Journals & SocietTweet
-
Mashup Score: 8Conference Update - 6 month(s) ago
Sparsentan Reduced Proteinuria in FSGS but Didn’t Slow Decline in Kidney Function Kelly Young In patients with focal segmental glomerulosclerosis (FSGS), sparsentan — a dual endothelin–angiotensin receptor antagonist — reduced proteinuria but didn’t affect kidney function, as compared with…
Source: m.n.nejm.orgCategories: General Medicine News, General Journals & SocietTweet
-
Mashup Score: 4Conference Update - 6 month(s) ago
Novel Budesonide Formulation May Preserve Kidney Function in IgAN Amy Herman A novel targeted-release formulation of budesonide (Nefecon) slowed declines in estimated glomerular filtration rate (eGFR) relative to placebo in patients with immunoglobulin A nephropathy (IgAN), according to 2-year…
Source: m.n.nejm.orgCategories: General Medicine News, General Journals & SocietTweet
-
Mashup Score: 17Conference Update - 6 month(s) ago
Sibeprenlimab Lowers Proteinuria in Patients with IgA Nephropathy Kelly Young Among patients with immunoglobulin A nephropathy receiving standard treatment, the addition of sibeprenlimab reduced proteinuria compared with placebo, according to an industry-funded, phase 2 study published in the New…
Source: m.n.nejm.orgCategories: General Medicine News, General Journals & SocietTweet
From #ASH23: new research on ibrutinib plus venetoclax for chronic lymphocytic leukemia and relapsed/refractory mantle-cell lymphoma, as well as an investigational oral factor D inhibitor for paroxysmal nocturnal hemoglobinuria. https://t.co/NiUPItUeLa https://t.co/vn4NCHiQlH